Oselusi SO, Dube P, Odugbemi AI, Akinyede KA, Ilori TL, Egieyeh E, Sibuyi NR, Meyer M, Madiehe AM, Wyckoff GJ, Egieyeh SA
While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions
10.3748/wjg.v24.i24.2567 27 GemelJ.SimonA
Making a choice between them involves considering individual goals, tolerance for administration methods, and potential side effects
[DOI] [PubMed] [Google Scholar] Commandeur J.N., Stijntjes G.J., Vermeulen N.P